2025
Addressing Peri-Device Leaks in Next-Generation Transcatheter Left Atrial Appendage Occluders: An Open Question
Roshanfar M, Jang S, Sinusas A, Wong S, Mosadegh B. Addressing Peri-Device Leaks in Next-Generation Transcatheter Left Atrial Appendage Occluders: An Open Question. Surgeries 2025, 6: 15. DOI: 10.3390/surgeries6010015.Peer-Reviewed Original ResearchPeri-device leakLeft atrial appendageFDA-approved devicesRisk of thrombo-embolic eventsNon-valvular atrial fibrillationLeft atrial appendage anatomyLong-term anticoagulationPercutaneous LAA occlusionCHA2DS2-VASc scoreThrombo-embolic eventsIncreased risk of strokeRisk of strokeCircular cross-sectionLeft atrial appendage occluderSystemic embolismAnticoagulant therapyLAA occlusionObservational registryCHA2DS2-VAScNon-pharmacological alternativeAdverse eventsAtrial fibrillationAtrial appendageClinical dataIncreased risk
2024
Anticoagulation Therapy for Venous Thromboembolism in the Pediatric Population: A Systematic Review and Meta-Analysis
Azzam M, Kawtharany H, Monagle P, Bercovitz R, Hamarsha Q, Alkhader A, Abou Zeid H, Mansour R, Patel P, Tabak C, Baghdadi S, Betensky M, Bhat R, Biss T, Branchford B, Brandao L, Chan A, Faustino E, Jaffray J, Jones S, Kerlin B, Kucine N, Kumar R, Male C, Pelland-Marcotte M, Raffini L, Raulji C, Sartain S, Takemoto C, Tarango C, Van Ommen H, Velez-Yanguas M, Vesely S, Wiernikowski J, Williams S, Wilson H, Woods G, Zia A, Mustafa R. Anticoagulation Therapy for Venous Thromboembolism in the Pediatric Population: A Systematic Review and Meta-Analysis. Blood 2024, 144: 1257-1257. DOI: 10.1182/blood-2024-212150.Peer-Reviewed Original ResearchRisk of biasCertainty of evidenceVenous thromboembolismPediatric patientsThrombus resolutionAll-cause mortalityThrombus recurrenceAC therapyAnticoagulant therapyAbsolute effectEvents of all-cause mortalityPediatric populationSystematic reviewNon-randomized Studies of InterventionsManagement of venous thromboembolismMeta-analysisStudies of interventionsConcerns related to riskNon-randomized observational studyNon-randomized studiesRecommendations AssessmentThrombus progressionBleeding eventsBleeding riskPortal hypertensionThe foundation for investigating factor XI as a target for inhibition in human cardiovascular disease
Ali A, Becker R. The foundation for investigating factor XI as a target for inhibition in human cardiovascular disease. Journal Of Thrombosis And Thrombolysis 2024, 57: 1283-1296. PMID: 38662114, PMCID: PMC11645312, DOI: 10.1007/s11239-024-02985-0.Peer-Reviewed Original ResearchConceptsCardiovascular diseaseCoronary syndromeChronic coronary syndromeFactor XIManagement of patientsSusceptible to pharmacological inhibitionAcute coronary syndromeHuman cardiovascular diseaseAnticoagulant therapyImmune dysregulationSystemic inflammationAtrial fibrillationClinical trialsPharmacological inhibitionTargeted drugsThrombosisIschemic strokeReparative capabilitiesPhenotypic expressionEnvironmental triggersOxidative stressDay-to-day patient careMolecular eventsSyndromeDiseaseFactor XI: structure, function and therapeutic inhibition
Ali A, Becker R. Factor XI: structure, function and therapeutic inhibition. Journal Of Thrombosis And Thrombolysis 2024, 57: 1315-1328. PMID: 38622277, PMCID: PMC11645426, DOI: 10.1007/s11239-024-02972-5.Peer-Reviewed Original ResearchFactor XI inhibitorsVitamin K antagonistsEnd-stage renal diseaseFactor XITraditional anticoagulantsSafety profileInherent risk of bleedingPhase 3 clinical trialsPhase 2 studyMultiple coagulation factorsRisk of bleedingFactor XI deficiencyIntrinsic pathway of coagulationPathway of coagulationFXI inhibitorsK antagonistsOral anticoagulantsAnticoagulant therapyTherapeutic anticoagulationVenous thromboembolismPreclinical studiesAtrial fibrillationClinical endpointsRenal diseaseClinical trialsAntithrombotic Treatment for Stroke Prevention in Cervical Artery Dissection: The STOP-CAD Study
Yaghi S, Shu L, Mandel D, Guerrero C, Henninger N, Muppa J, Affan M, Lodhi O, Heldner M, Antonenko K, Seiffge D, Arnold M, Omran S, Crandall R, Lester E, Mena D, Arauz A, Nehme A, Boulanger M, Touze E, Sousa J, Sargento-Freitas J, Barata V, Castro-Chaves P, Brito M, Khan M, Mallick D, Rothstein A, Khazaal O, Kaufmann J, Engelter S, Traenka C, de Sousa D, Soares M, Rosa S, Zhou L, Gandhi P, Field T, Mancini S, Metanis I, Leker R, Pan K, Dantu V, Baumgartner K, Burton T, Von Rennenberg R, Nolte C, Choi R, MacDonald J, Shahripour R, Guo X, Ghannam M, AlMajali M, Samaniego E, Sanchez S, Rioux B, Zine-Eddine F, Poppe A, Fonseca A, Baptista M, Cruz D, Romoli M, De Marco G, Longoni M, Keser Z, Griffin K, Kuohn L, Frontera J, Amar J, Giles J, Zedde M, Pascarella R, Grisendi I, Nzwalo H, Liebeskind D, Molaie A, Cavalier A, Kam W, Mac Grory B, Al Kasab S, Anadani M, Kicielinski K, Eltatawy A, Chervak L, Chulluncuy-Rivas R, Aziz Y, Bakradze E, Tran T, Rodrigo-Gisbert M, Requena M, Velez F, Gracia J, Mudassani V, de Havenon A, Vishnu V, Yaddanapudi S, Adams L, Browngoehl A, Ranasinghe T, Dunston R, Lynch Z, Penckofer M, Siegler J, Mayer S, Willey J, Zubair A, Cheng Y, Sharma R, Marto J, Ferreira V, Klein P, Nguyen T, Asad S, Sarwat Z, Balabhadra A, Patel S, Secchi T, Martins S, Mantovani G, Kim Y, Krishnaiah B, Elangovan C, Lingam S, Quereshi A, Fridman S, Alvarado A, Khasiyev F, Linares G, Mannino M, Terruso V, Vassilopoulou S, Tentolouris V, Martinez-Marino M, Wall V, Indraswari F, Jamal S, Liu S, Alvi M, Ali F, Sarvath M, Morsi R, Kass-Hout T, Shi F, Zhang J, Sokhi D, Said J, Simpkins A, Gomez R, Sen S, Ghani M, Elnazeir M, Xiao H, Kala N, Khan F, Stretz C, Mohammadzadeh N, Goldstein E, Furie K. Antithrombotic Treatment for Stroke Prevention in Cervical Artery Dissection: The STOP-CAD Study. Stroke 2024, 55: 908-918. PMID: 38335240, DOI: 10.1161/strokeaha.123.045731.Peer-Reviewed Original ResearchCervical artery dissectionInverse probability of treatment weightingIschemic stroke riskIschemic strokeAntiplatelet therapyArtery dissectionCox regressionOcclusive dissectionCervical artery dissection patientsStroke riskProbability of treatment weightingBenefits of anticoagulationOptimal stroke prevention strategyStroke prevention strategiesReducing ischemic stroke riskAnticoagulant therapyAntithrombotic treatmentProspective studyCross-over approachRandomized trialsAnticoagulationCompare outcomesPrevention strategiesTreatment weightingHigh risk
2023
Perioperative Acute Ischemic Stroke in Patients with Atrial Fibrillation
Shu L, Jiang W, Xiao H, Henninger N, Nguyen T, Siegler J, de Havenon A, Goldstein E, Mandel D, Rana M, Al‐Mufti F, Frontera J, Furie K, Yaghi S. Perioperative Acute Ischemic Stroke in Patients with Atrial Fibrillation. Annals Of Neurology 2023, 94: 321-329. PMID: 37183768, DOI: 10.1002/ana.26678.Peer-Reviewed Original ResearchConceptsAcute ischemic strokeAtrial fibrillationPerioperative acute ischemic strokeDiagnosis-related groupsRisk factors-VASc scoreActive cancerHigher CHA<sub>2</sub> DS<sub>2</sub> VASc score. TheElective proceduresInternational Classification of DiseasesRisk factors of acute ischemic strokeScoring systemIschemic strokeClassification of DiseasesNeurological surgeryDays of dischargeLogistic regression modelsNationwide Readmissions DatabaseElective surgical proceduresAnticoagulant therapyInternational ClassificationPeriprocedural periodRenal failureSurgical typeAdult patientsManagement of Anticoagulation Therapy in ECMO-Associated Ischemic Stroke and Intracranial Hemorrhage
Prokupets R, Kannapadi N, Chang H, Caturegli G, Bush E, Kim B, Keller S, Geocadin R, Whitman G, Cho S, Acton M, Rando H, Alejo D, Calligy K, Anderson S, Shou B, Sussman M, Wilcox C, Zhang L, Brown P, Peeler A. Management of Anticoagulation Therapy in ECMO-Associated Ischemic Stroke and Intracranial Hemorrhage. Innovations Technology And Techniques In Cardiothoracic And Vascular Surgery 2023, 18: 49-57. PMID: 36628944, PMCID: PMC10236353, DOI: 10.1177/15569845221141702.Peer-Reviewed Original ResearchConceptsAcute ischemic strokeIntracranial hemorrhageVA-ECMOVV-ECMOAnticoagulation managementManagement of anticoagulant therapyAntithrombotic therapy managementICH expansionVA-ECMO patientsVenovenous (VVIschemic strokeResumption of anticoagulationExtracorporeal membrane oxygenationCohort of patientsTertiary care centerOptimal anticoagulation managementDiagnosis of acute ischemic strokeIn-hospital mortalityIntracranial hemorrhage survivorsAcute ischemic stroke survivorsAnticoagulation reversalECMO patientsAnticoagulant therapyThromboembolic eventsMembrane oxygenation
2021
OpenSAFELY: impact of national guidance on switching anticoagulant therapy during COVID-19 pandemic
Collaborative T, Curtis HJ, MacKenna B, Walker AJ, Croker R, Mehrkar A, Morton C, Bacon S, Hickman G, Inglesby P, Bates C, Evans D, Ward T, Cockburn J, Davy S, Bhaskaran K, Schultze A, Rentsch CT, Williamson E, Hulme W, Tomlinson L, Mathur R, Drysdale H, Eggo RM, Wong AY, Forbes H, Parry J, Hester F, Harper S, Douglas I, Smeeth L, Goldacre B. OpenSAFELY: impact of national guidance on switching anticoagulant therapy during COVID-19 pandemic. Open Heart 2021, 8: e001784. PMID: 34785588, PMCID: PMC8595296, DOI: 10.1136/openhrt-2021-001784.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnticoagulantsBlood CoagulationBlood Coagulation TestsCOVID-19Drug MonitoringDrug PrescriptionsDrug SubstitutionDrug UtilizationEnglandFactor Xa InhibitorsFemaleHumansMaleMiddle AgedPatient SafetyPractice Guidelines as TopicPractice Patterns, Physicians'Primary Health CareRetrospective StudiesRisk AssessmentRisk FactorsState MedicineWarfarinConceptsWarfarin patientsNational Health ServiceCOVID-19 pandemicNational guidanceCare home residencyINR test resultsRenal function testsFrequent blood testingSafety alertsRoutine clinical dataAtrial fibrillation diagnosisElevated INRMedication changesOral anticoagulantsAnticoagulant therapyCohort studyAppropriate patientsINR testsFunction testsBlood testingPrimary careClinical dataDOACPatientsWarfarinIschaemic stroke on anticoagulation therapy and early recurrence in acute cardioembolic stroke: the IAC study
Yaghi S, Henninger N, Giles JA, Guerrero C, Mistry E, Liberman AL, Asad D, Liu A, Nagy M, Kaushal A, Azher I, Mac Grory B, Fakhri H, Espaillat K, Pasupuleti H, Martin H, Tan J, Veerasamy M, Esenwa C, Cheng N, Moncrieffe K, Moeini-Naghani I, Siddu M, Scher E, Trivedi T, Furie KL, Keyrouz SG, Nouh A, de Havenon A, Khan M, Smith EE, Gurol ME. Ischaemic stroke on anticoagulation therapy and early recurrence in acute cardioembolic stroke: the IAC study. Journal Of Neurology Neurosurgery & Psychiatry 2021, 92: 1062-1067. PMID: 33903185, PMCID: PMC8448925, DOI: 10.1136/jnnp-2021-326166.Peer-Reviewed Original ResearchConceptsRecurrent ischemic eventsSymptomatic intracranial hemorrhageIschemic strokeIschemic eventsAtrial fibrillationAnticoagulation therapyAcute cardioembolic strokeAnticoagulation-naïve patientsInitiation of anticoagulationStroke prevention measuresComprehensive stroke centerIschemic stroke patientsAcute ischemic strokeCox regression analysisSecondary prevention strategiesCox hazard modelSICH riskAnticoagulant therapyAnticoagulation statusStroke centersCardioembolic strokeAF patientsConsecutive patientsEarly recurrenceIntracranial hemorrhage
2020
Anticoagulation in COVID-19: Effect of Enoxaparin, Heparin, and Apixaban on Mortality
Billett H, Reyes-Gil M, Szymanski J, Ikemura K, Stahl L, Lo Y, Rahman S, Gonzalez-Lugo J, Kushnir M, Barouqa M, Golestaneh L, Bellin E. Anticoagulation in COVID-19: Effect of Enoxaparin, Heparin, and Apixaban on Mortality. Thrombosis And Haemostasis 2020, 120: 1691-1699. PMID: 33186991, PMCID: PMC7869055, DOI: 10.1055/s-0040-1720978.Peer-Reviewed Original ResearchConceptsD-dimer levelsD-dimerProphylactic useDecreased mortalityHigher D-dimer levelsAssociated with decreased mortalityIntensive care unit admissionAssociated with disease severityAssociated with increased mortalityGlomerular filtration rateLogistic regression analysisEffect of enoxaparinProthrombotic parametersTransfusion requirementsAnticoagulant therapyUnit admissionFiltration rateCohort studyClinical trialsAnticoagulationApixabanOxygen saturationEnoxaparinIllness severityDisease severityAcute Brain Injury in Infant Venoarterial Extracorporeal Membrane Oxygenation: An Autopsy Study.
Caturegli G, Cho S, White B, Chen L. Acute Brain Injury in Infant Venoarterial Extracorporeal Membrane Oxygenation: An Autopsy Study. Pediatric Critical Care Medicine 2020, 22: 297-302. PMID: 33055528, DOI: 10.1097/pcc.0000000000002573.Peer-Reviewed Original ResearchConceptsExtracorporeal membrane oxygenationVenoarterial extracorporeal membrane oxygenationAcute brain injuryHypoxic-ischemic brain injuryMembrane oxygenationMedian ageIntracranial hemorrhageExtracorporeal membrane oxygenation support durationExtracorporeal membrane oxygenation durationExtracorporeal membrane oxygenation initiationExtracorporeal membrane oxygenation patientsBrain injuryElevated liver enzymesAssociated with acute brain injuryApgar scoreGestational ageOxygenation durationTiming of acute brain injuryHepatic impairmentAnticoagulant therapyPathology recordsBirth weightOxygenation patientsOxygenation initiationAutopsied patientsAntiplatelet patterns and outcomes in patients with atrial fibrillation not prescribed an anticoagulant after stroke
Chang K, Xian Y, Zhao X, Mi X, Matsouaka R, Schwamm L, Shah S, Lytle B, Smith E, Bhatt D, Fonarow G, Hsu J. Antiplatelet patterns and outcomes in patients with atrial fibrillation not prescribed an anticoagulant after stroke. International Journal Of Cardiology 2020, 321: 88-94. PMID: 32805327, DOI: 10.1016/j.ijcard.2020.08.011.Peer-Reviewed Original ResearchConceptsAcute ischemic strokeAntiplatelet therapyAntithrombotic therapyIschemic strokeTherapy prescriptionOral anticoagulationUnadjusted ratesGuidelines-Stroke registryService beneficiaries 65Retrospective cohort studyOral anticoagulant therapyAnticoagulant therapyCohort studyComposite endpointPrimary outcomeAtrial fibrillationAtrial flutterPotential confoundersNeurologic/Medicare beneficiariesMedicare feeTherapyStrokePatientsMortalityAnticoagulation Type and Early Recurrence in Cardioembolic Stroke
Yaghi S, Mistry E, Liberman AL, Giles J, Asad SD, Liu A, Nagy M, Kaushal A, Azher I, Mac Grory B, Fakhri H, Brown Espaillat K, Pasupuleti H, Martin H, Tan J, Veerasamy M, Esenwa C, Cheng N, Moncrieffe K, Moeini-Naghani I, Siddu M, Scher E, Trivedi T, Lord A, Furie K, Keyrouz S, Nouh A, Leon Guerrero CR, de Havenon A, Khan M, Henninger N. Anticoagulation Type and Early Recurrence in Cardioembolic Stroke. Stroke 2020, 51: 2724-2732. PMID: 32757753, PMCID: PMC7484360, DOI: 10.1161/strokeaha.120.028867.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAnticoagulantsAtrial FibrillationBrain IschemiaEmbolismFemaleHeart DiseasesHeparin, Low-Molecular-WeightHumansIncidenceIntracranial HemorrhagesMaleMiddle AgedNeuroimagingRecurrenceRegistriesRetrospective StudiesRisk AssessmentStrokeTreatment OutcomeUnited StatesWarfarinConceptsSymptomatic intracranial hemorrhageRecurrent ischemic eventsLow molecular weight heparinAcute ischemic strokeMolecular weight heparinIschemic eventsIntracranial hemorrhageIschemic strokeAtrial fibrillationAnalysis inclusion criteriaEarly recurrenceWeight heparinInclusion criteriaSeparate Cox regression analysesComprehensive stroke centerLarge prospective studiesOral anticoagulant therapyCox regression analysisCox regression modelAnticoagulation typeDOAC treatmentStroke RegistryAnticoagulant therapyCardioembolic strokeStroke centers
2019
Stroke prophylaxis in critically-ill patients with new-onset atrial fibrillation
Schoaps RS, Quintili A, Bonavia A, Carr ZJ, Lehman EB, Abendroth T, Karamchandani K. Stroke prophylaxis in critically-ill patients with new-onset atrial fibrillation. Journal Of Thrombosis And Thrombolysis 2019, 48: 394-399. PMID: 30963394, DOI: 10.1007/s11239-019-01854-5.Peer-Reviewed Original ResearchConceptsNew-onset atrial fibrillationCHA2DS2-VASc scoreOral anticoagulant therapyOral anticoagulantsIll patientsStroke prophylaxisAnticoagulant therapyHospital dischargeAtrial fibrillationEffective stroke prophylaxisOnset atrial fibrillationStroke/TIACongestive heart failureLong-term incidenceElectronic medical recordsEligible patientsICU survivorsAdult patientsHeart failureThromboembolic diseaseMedical recordsHigh incidencePatientsAnticoagulantsStudy period
2018
Underuse of Vitamin K Antagonist and Direct Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation: A Contemporary Review
Hsu JC, Freeman JV. Underuse of Vitamin K Antagonist and Direct Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation: A Contemporary Review. Clinical Pharmacology & Therapeutics 2018, 104: 301-310. PMID: 29328506, DOI: 10.1002/cpt.1024.Peer-Reviewed Original ResearchConceptsAtrial fibrillationStroke preventionVitamin K antagonistsDirect oral anticoagulantsNonvalvular AF patientsOral anticoagulant therapyRisk of strokeSpecial patient populationsSerious clinical problemOAC therapyK antagonistsOral anticoagulantsAnticoagulant therapyAF patientsPatient populationLeading causeClinical problemPatientsSignificant deleterious impactPreventionFibrillationTherapyContemporary reviewStrokeUnderuse
2017
Association Between Previous Use of Antiplatelet Therapy and Intracerebral Hemorrhage Outcomes
Khan N, Siddiqui F, Goldstein J, Cox M, Xian Y, Matsouaka R, Heidenreich P, Peterson E, Bhatt D, Fonarow G, Schwamm L, Smith E. Association Between Previous Use of Antiplatelet Therapy and Intracerebral Hemorrhage Outcomes. Stroke 2017, 48: 1810-1817. PMID: 28596454, DOI: 10.1161/strokeaha.117.016290.Peer-Reviewed Original ResearchConceptsAntiplatelet therapyIntracerebral hemorrhageHospital mortalityPrevious useDiagnosis of ICHCombination antiplatelet therapyGuidelines-Stroke hospitalsPrestroke antiplatelet therapyTerms of comorbiditiesOral anticoagulant therapyIntracerebral hemorrhage outcomesAPT groupHigh-risk profileHospital presentationAnticoagulant therapyBaseline characteristicsAntiplatelet agentsHospital characteristicsHigh riskPatientsRisk profileMortalityTherapyAPT useComorbiditiesOral anticoagulation management in patients with atrial fibrillation undergoing cardiac implantable electronic device implantation
Black‐Maier E, Kim S, Steinberg BA, Fonarow GC, Freeman JV, Kowey PR, Ansell J, Gersh BJ, Mahaffey KW, Naccarelli G, Hylek EM, Go AS, Peterson ED, Piccini JP, Investigators F. Oral anticoagulation management in patients with atrial fibrillation undergoing cardiac implantable electronic device implantation. Clinical Cardiology 2017, 40: 746-751. PMID: 28543401, PMCID: PMC5638096, DOI: 10.1002/clc.22726.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAgedAged, 80 and overAnticoagulantsAtrial FibrillationCardiac Pacing, ArtificialCardiac Resynchronization TherapyCardiac Resynchronization Therapy DevicesDefibrillators, ImplantableDrug Administration ScheduleDrug SubstitutionElectric CountershockFemaleHemorrhageHumansMaleMiddle AgedPacemaker, ArtificialRegistriesRisk FactorsStrokeTime FactorsTreatment OutcomeConceptsCardiac implantable electronic device implantationCIED implantationNOAC patientsAnticoagulation managementAF patientsAtrial fibrillationDevice implantationOral anticoagulation managementHigher creatinine clearanceManagement of anticoagulationOral anticoagulation therapyBetter Informed TreatmentOral anticoagulant therapyAtrial fibrillation patientsValvular heart diseaseBridging anticoagulationConcomitant aspirinInterrupted warfarinOAC therapyAnticoagulation strategiesAnticoagulation therapyOral anticoagulantsPeriprocedural riskAdverse eventsAnticoagulant therapyIncidence and Predictors of Left Atrial Appendage Thrombus in Patients Treated With Nonvitamin K Oral Anticoagulants Versus Warfarin Before Catheter Ablation for Atrial Fibrillation
Wyrembak J, Campbell KB, Steinberg BA, Bahnson TD, Daubert JP, Velazquez EJ, Samad Z, Atwater BD. Incidence and Predictors of Left Atrial Appendage Thrombus in Patients Treated With Nonvitamin K Oral Anticoagulants Versus Warfarin Before Catheter Ablation for Atrial Fibrillation. The American Journal Of Cardiology 2017, 119: 1017-1022. PMID: 28153350, DOI: 10.1016/j.amjcard.2016.12.008.Peer-Reviewed Original ResearchConceptsRoutine transesophageal echocardiographyAtrial appendage thrombusLAA thrombusTransesophageal echocardiographyVASc scoreAppendage thrombusNonvitamin K oral anticoagulantsLeft atrial appendage thrombusSingle-center retrospective studyLower LAA velocityTEE-related complicationsOral anticoagulant therapyAtrial fibrillation ablationLAA velocityNOAC therapyOral anticoagulantsAF ablationAnticoagulant therapyCatheter ablationFibrillation ablationAtrial fibrillationRetrospective studyTEE procedureLower incidenceNOACs
2016
Risk stratification, perioperative and periprocedural management of the patient receiving anticoagulant therapy
Oprea AD, Noto CJ, Halaszynski TM. Risk stratification, perioperative and periprocedural management of the patient receiving anticoagulant therapy. Journal Of Clinical Anesthesia 2016, 34: 586-599. PMID: 27687455, DOI: 10.1016/j.jclinane.2016.06.016.Peer-Reviewed Original ResearchConceptsPeriprocedural managementPerioperative periodInterventional pain proceduresRandomized clinical trialsAntithrombotic therapyAnticoagulant therapyPerioperative managementThromboembolic complicationsCoronary diseaseRisk stratificationAtrial fibrillationOutpatient settingPain proceduresClinical trialsRegional anesthesiaClinical judgmentUS populationTherapeutic useTime pointsAnticoagulantsTherapySubsequent increaseSpecial considerationAnticoagulationComplications
2011
Impact of Diabetes Mellitus on the Safety and Effectiveness of Bivalirudin in Patients With Acute Myocardial Infarction Undergoing Primary Angioplasty Analysis From the HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) Trial
Witzenbichler B, Mehran R, Guagliumi G, Dudek D, Huber K, Kornowski R, Stuckey T, Fahy M, Parise H, Stone G. Impact of Diabetes Mellitus on the Safety and Effectiveness of Bivalirudin in Patients With Acute Myocardial Infarction Undergoing Primary Angioplasty Analysis From the HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) Trial. JACC Cardiovascular Interventions 2011, 4: 760-768. PMID: 21777884, DOI: 10.1016/j.jcin.2011.04.008.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryAntithrombinsCoronary AngiographyDiabetes MellitusDose-Response Relationship, DrugDouble-Blind MethodElectrocardiographyFemaleFollow-Up StudiesHirudinsHumansHypoglycemic AgentsMaleMiddle AgedMyocardial InfarctionPeptide FragmentsProspective StudiesRecombinant ProteinsStentsSurvival RateTime FactorsTreatment OutcomeConceptsGlycoprotein IIb/IIIa inhibitorsST-segment elevation myocardial infarctionPrimary percutaneous coronary interventionHORIZONS-AMI trialDiabetes mellitusDiabetic patientsMyocardial infarctionPrimary PCIMajor adverse cardiac eventsIIb/IIIa inhibitorsEffectiveness of bivalirudinEfficacy of bivalirudinAdverse cardiac eventsAcute coronary syndromeElevation myocardial infarctionPercutaneous coronary interventionAcute myocardial infarctionMajor bleedingCardiac mortalityCoronary syndromeAnticoagulant therapyCardiac eventsCoronary interventionCardiac deathUnfractionated heparin
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply